Tonix Pharmaceuticals Holding Corp
Research Tonix Pharmaceuticals Holding Corp (TNXP) on Bullrun: market cap USD 122.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTNXP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 122.58M
- Financial periodQ2 2026
- RevenueUSD 13.54M
- Net income-USD 40.55M
- Free cash flow-USD 42.83M
- Gross margin94.8%
Valuation Snapshot
latest market cap is USD 122.58M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 13.11M | -USD 124.02M | -USD 103.21M | 49.3% | -14.57 | USD 207.64M | USD 1.31M | USD 245.15M |
| FY2024 | USD 10.09M | -USD 130.04M | -USD 61.05M | 23.1% | -176.6 | USD 98.78M | USD 7.49M | USD 139.56M |
| FY2023 | USD 7.77M | -USD 116.66M | -USD 109.90M | 39.0% | -14720.25 | USD 24.95M | USD 8.91M | USD 105.53M |
| FY2022 | USD 0 | -USD 110.22M | -USD 146.20M | n/a | -20.01 | USD 120.23M | USD 760.00K | USD 207.18M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 122.58M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 114.92M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 144.73M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 23.42M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 22.62M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 184.32M | n/a | n/a | n/a |
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tonix Pharmaceuticals Holding Corp's market cap?
Tonix Pharmaceuticals Holding Corp's market capitalization is USD 122.58M.
What does Tonix Pharmaceuticals Holding Corp do?
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.